Lilly's Cyramza closer to first-line lung cancer use after O...

NICE rejects Roche's Polivy combination in advanced lymphoma

England’s NHS should not fund Roche’s Polivy (polatuzumab vedotin) in combination with rituximab and bendamustine for adults with a form of advanced lymphoma, NICE has said in first draft g

Roche hops on Bicycle’s drug discovery platform for cancer

GSK begins cancer cell therapy tie-up with Immatics

Cancer biotech Immatics has begun a collaboration with GlaxoSmithKline to develop novel therapies built around its T-cell-based technology.

FDA to quickly review Roche's chemo-free lung cancer regimen

Roche’s challenge to Merck & Co’s immunotherapy Keytruda in first line lung cancer has gathered momentum after the FDA agreed to a fast review of Tecentriq monotherapy, preventing the n

ALX Oncology cancer drug claims two FDA fast-track reviews